Lates News

According to information from Roche Pharmaceuticals, the National Medical Products Administration (NMPA) of China has officially approved the use of Polivy (English trade name: Polivy, English generic name: Polatuzumab Vedotin for Injection) in combination with rituximab, gemcitabine, and oxaliplatin (Pola-R-GemOx) for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for hematopoietic stem cell transplantation.